Literature DB >> 33205042

Polypharmacy and Depressive Symptoms in U.S.-Born Mexican American Older Adults.

Shervin Assari1, Cheryl Wisseh2, Mohammed Saqib3, Hamid Helmi4, Mohsen Bazargan1,5.   

Abstract

BACKGROUND: Although some studies have suggested a link between polypharmacy and poor mental health, less is known about the association between polypharmacy and depressive symptomology among U.S.-born older Mexican Americans. AIM: This study aimed to test the association between polypharmacy and depressive symptoms in U.S.-born older Latino Americans.
MATERIALS AND METHODS: Data came from the Sacramento Area Latino Study on Aging (SALSA 2008). A total of 691 U.S.-born older (age >= 65) Mexican Americans entered this analysis. Polypharmacy was the independent variable. Level of depressive symptoms was the outcome. Age, gender, socioeconomic status (education, income, and employment), retirement status, health (chronic medical conditions, self-rated health, and activities of daily living), language, acculturation, and smoking were the covariates. A linear regression model was used to analyze the data.
RESULTS: We found a positive association between polypharmacy and depressive symptoms, which was above and beyond demographic factors, socioeconomic status, physical health, health behaviors, language, acculturation, and health insurance.
CONCLUSION: Polypharmacy is linked to depressive symptoms in U.S.-born older Mexican Americans. More research is needed to test the effects of reducing inappropriate polypharmacy on mental well-being of first and second generation older Mexican Americans. There is also a need to study the role of drug-drug interaction in explaining the observed link between polypharmacy and depressive symptoms.

Entities:  

Keywords:  Hispanics; Latino; Mexican Americans; depressive symptoms; ethnic groups; ethnicity; polypharmacy

Year:  2019        PMID: 33205042      PMCID: PMC7668560          DOI: 10.3390/psych1010038

Source DB:  PubMed          Journal:  Psych        ISSN: 2624-8611


  45 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

Review 2.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Combined Racial and Gender Differences in the Long-Term Predictive Role of Education on Depressive Symptoms and Chronic Medical Conditions.

Authors:  Shervin Assari
Journal:  J Racial Ethn Health Disparities       Date:  2016-06-07

Review 4.  A literature review: polypharmacy protocol for primary care.

Authors:  Mary Skinner
Journal:  Geriatr Nurs       Date:  2015-06-27       Impact factor: 2.361

Review 5.  Interventions to reduce antipsychotic polypharmacy: a systematic review.

Authors:  Hideaki Tani; Hiroyuki Uchida; Takefumi Suzuki; Yasuo Fujii; Masaru Mimura
Journal:  Schizophr Res       Date:  2012-11-14       Impact factor: 4.939

6.  Using the Revised Acculturation Rating Scale for Mexican Americans (ARSMA-II) with Older Adults.

Authors:  Daniel E Jimenez; Heather L Gray; Michael Cucciare; Sheba Kumbhani; Dolores Gallagher-Thompson
Journal:  Hisp Health Care Int       Date:  2010-03-01

7.  Cross-Country Differences in the Additive Effects of Socioeconomics, Health Behaviors and Medical Comorbidities on Disability among Older Adults with Heart Disease.

Authors:  Shervin Assari
Journal:  J Tehran Heart Cent       Date:  2015-01-08

8.  Cross-country differences in the association between diabetes and disability.

Authors:  Shervin Assari; Reza Moghani Lankarani; Maryam Moghani Lankarani
Journal:  J Diabetes Metab Disord       Date:  2014-01-06

9.  Race/Ethnicity, Socioeconomic Status, and Polypharmacy among Older Americans.

Authors:  Shervin Assari; Mohsen Bazargan
Journal:  Pharmacy (Basel)       Date:  2019-04-25

10.  Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.

Authors:  Kerryn S Armstrong; Henk Temmingh
Journal:  Braz J Psychiatry       Date:  2017-02-06       Impact factor: 2.697

View more
  1 in total

1.  The pattern of medication use, and determinants of the prevalence of polypharmacy among patients with a recent history of depressive disorder: results from the pars cohort study.

Authors:  Mehrnoosh Ghaed-Sharaf; Sanam Hariri; Hossein Poustchi; Maryam Nourollahi; Sara Khani; Erfan Taherifard; Zahra Mohammadi; Maryam Hadipour; Rasoul Sabaei; Abdullah Gandomkar; Fatemeh Malekzadeh; Hossein Molavi Vardanjani
Journal:  BMC Psychol       Date:  2022-01-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.